Background: Fatigue is a common symptom in multiple sclerosis (MS) and often restricts societal participation. Cognitive behavioral therapy (CBT) may alleviate MS-related fatigue, but evidence in literature is inconclusive. Objective: To evaluate the effectiveness of CBT to improve MS-related fatigue and participation. Methods: In a multi-center, assessor-masked, randomized controlled trial, participants with severe MSrelated fatigue were assigned to CBT or control treatment. CBT consisted of 12 individual sessions with a psychologist trained in CBT, the control treatment consisted of three consultations with a MS nurse, both delivered over 16 weeks. Assessments were at baseline, 8, 16 (i.e. post-intervention), 26, and 52 weeks post-baseline. Primary outcomes were the Checklist Individual Strength-fatigue subscale (CIS20r fatigue) and the Impact on Participation and Autonomy questionnaire (IPA). Data were analyzed according to the intention-to-treat principle, using mixed-model analysis. Results: Between 2011 and 2014, 91 patients were randomized (CBT: n = 44; control: n = 47). Betweengroup analysis showed a positive post-intervention effect for CBT on CIS20r fatigue (T16: −6.7 (95% confidence interval (CI) = −10.7; −2.7) points) that diminished during follow-up (T52: 0.5 (95% CI = −3.6; 4.4)). No clinically relevant effects were found on societal participation. Conclusion: Severe MS-related fatigue can be reduced effectively with CBT in the short term. More research is needed on how to maintain this effect over the long term.
Introduction
Patients with multiple sclerosis (MS) frequently report fatigue as one of their most troublesome symptoms. [1] [2] [3] It negatively affects societal participation and health-related quality of life, 4, 5 but remains poorly understood. 2 Current approaches to decrease MS-related fatigue include pharmacological and non-pharmacological treatments or a combination of these approaches.
A recent review concluded that non-pharmacological interventions (both exercise and psychological/educational interventions) appear to reduce fatigue more than commonly prescribed pharmacological treatments. 6, 7 Furthermore, it appears that psychological interventions can be a clinically feasible and cost-effective treatment for MS-related fatigue. 7 To provide a starting point for the treatment of MS-related fatigue, Van Kessel and Moss-Morris 8 developed a cognitive behavioral model to explain the persistence of MS-related fatigue. This model encompasses both disease-related factors and psychological factors identified in the literature. According to this model, disease-related factors trigger fatigue in MS, and cognitive, emotional, and behavioral factors then determine the extent to which fatigue influences daily life. 8 In addition, this theoretical model suggests that the combination of these factors may perpetuate or worsen MS-related fatigue. This basic understanding is of interest when considering the effectiveness of non-pharmacological treatments. Cognitive behavioral therapy (CBT) for MS-related fatigue aims to influence the dysfunctional cognitions, behaviors, and emotions that perpetuate fatigue. It has been suggested that MS-related fatigue can be treated and decreased instead of managed and accepted. 9 Therapists will challenge the meaning of dysfunctional cognitions and aim to change the behavior of patients with MS-related fatigue and emphasize more realistic cognitions, emotions, and behaviors. 8 Together these changes can break the vicious circle of fatigue. 8 A recent meta-analysis concluded that CBT has a moderately positive short-term effect on MS-related fatigue. 10 However, this effect decreases with cessation of treatment. When the TREFAMS (TREating FAtigue in patients with MS)-CBT study began, the only available randomized controlled trial (RCT) was that of Van Kessel et al. 11 While this study served as an example for the TREFAMS-CBT study, it had one major limitation: the same therapist provided both the CBT and the relaxation training. 11 This increases the risk of contamination between study groups and limits generalizability to other clinical settings and to other therapists.
We aimed to assess the effectiveness of CBT in decreasing fatigue and improving societal participation in patients with MS, compared to MS nurse consultations. The CBT therapists were certified psychologists and CBT was compared to standardized control intervention provided by MS nurses. 12 Furthermore, the study included an extended 1-year post-randomization follow-up and only patients with severe MS-related fatigue were included.
Methods

Study design and participants
The TREFAMS-CBT study (trial registration: ISRCTN58583714) is part of the TREFAMS-ACE multi-trial research program designed to study the effectiveness of aerobic training, CBT, and energy conservation management in the treatment of MS-related fatigue. The design of the three individual trials is identical and has been outlined previously. 12 The TREFAMS-ACE study 12 was approved by the Medical Ethics Committee of the VU University Medical Center. Fonds NutsOhra (grant number ZonMw 89000005) funded the program. The Consolidated Standards of Reporting Trials guidelines for non-pharmacological trials (CONSORT statement) were used to standardize reporting. 13 Participants were recruited in three Dutch centers (VU University Medical Center in Amsterdam, the Radboud University Medical Centre, and the St.
Maartenskliniek in Nijmegen), via referral from physicians at regional centers, personal invitation letters, advertisement via Internet and posters/pamphlets. Interested patients were invited for an intake interview to provide additional information about the trial and to test for eligibility. The intake consisted of a structured medical history taking, a structured physical examination, questionnaires, and a blood draw. Main eligibility criteria were as follows: (a) definitive diagnosis of MS, (b) experience of severe fatigue (CIS20r fatigue ⩾35), (c) be ambulatory (Expanded Disability Status Scale (EDSS) score ⩽6), (d) no signs of exacerbation, (e) no clinical depression (Hospital Anxiety and Depression Scale (HADS depression) score >11), and (f) no severe comorbid disorders (medical history taking and results of the blood draw). Full inclusion criteria are published. 12 Prior to inclusion, written informed consent was obtained from all participants.
Randomization and masking
Randomization was performed using concealed computerized block-wise randomization, stratified by treatment center. The block size of 8 was disclosed after finishing all follow-up measurements. An independent investigator, not the assessors, carried out the randomization and informed the patient and therapist about the therapy allocation. The assessors were blinded for the treatment, and patients and therapists were instructed not to unblind the assessors. The analyses were performed blinded to participant treatment allocation.
Procedures
The treatment procedure began in December 2011 and ended in December 2014. A more detailed description (completed TIDieR (template for intervention description and replication) checklist) of the CBT intervention and the control intervention is available in Supplementary Appendix 1 and Supplementary Appendix 2. 1, 2 The patients randomly allocated to the CBT received 12 sessions of individual face-to-face therapy spread over a 4-month period (8 sessions in the first 2 months, 4 sessions in the last 2 months). The CBT protocol consists of 10 modules: formulating goals, regulating sleep/wake pattern, changing beliefs regarding MS, changing beliefs regarding fatigue, reduce the focus on fatigue, regulation of physical, social, and mental activity, addressing the role of the environment, and handling pain (more information about the modules is available in Supplementary Appendix 2). The intervention was patient-tailored: questionnaires with predefined cut-off scores and information from the intake session with the psychologist were used to determine which modules were indicated for the patient. After an intake session in which information was provided on the cognitive behavioral model of MS-related fatigue and CBT, patients started by formulating their treatment goals. The following sessions addressed the fatigue-maintaining cognitions and behaviors and were aimed at realizing the set treatment goals. The final therapy sessions focused on integrating the obtained skills into daily life and on how patients should handle relapses of fatigue. All CBT therapists were state-certified healthcare psychologists who received a 3-day course on how to deliver CBT according to the TREFAMS-CBT protocol. Furthermore, the CBT therapists received supervision every other week from an experienced CBT psychologist.
The control intervention consisted of a protocolled treatment by an experienced MS nurse that included three consultations of 45 minutes over a 4-month period, and intended. It was developed to control for attention from a MS-professional and information about fatigue, that is, to control for non-specific treatment effects, this should thus not be considered as an active or lower dose treatment. The study protocol did not allow the MS nurses to provide active advices or refer patients to a psychologist or other healthcare professionals for the treatment of fatigue. During the consultations, the patient received written and oral information about MS-related fatigue, and patients discussed their personal experiences in coping with fatigue and other fatigue-related issues. The consultations were guided by the questions that patients had about their fatigue and the provided booklet. A more detailed description of the CBT intervention and the MS nurse consultations is available elsewhere (Supplementary Appendix 1 and Supplementary Appendix 2). 12 Outcomes Outcome measures were completed at baseline, 8 weeks (T8), 16 weeks (T16; i.e. post-intervention), 26 weeks (T26), and 52 weeks (T52) of follow-up. All time-points were used in the longitudinal analyses of the primary and secondary outcomes. Baseline and T52 measurements included socio-demographic and disease characteristics. The primary outcome measures were the CIS20r fatigue and the IPA. 14, 15 Secondary outcomes for fatigue were Fatigue Severity Scale (FSS), 16 Modified Fatigue Impact Scale (MFIS), 17 and the CIS20r subscales physical activity, concentration, and motivation. 14 Secondary outcomes for participation were the Medical Outcome Study Short Form 36 18 (SF36) and the Rehabilitation Activities Profile (RAP). 19 The CIS20r subscale fatigue 14 was used to measure MS-related fatigue. It consists of eight statements that are rated on a 7-point scale; the score ranges from 8 to 56 points. All participants needed a score of 35 or higher on the CIS20r fatigue before enrollment in the TREFAMS study. A higher score means more severe fatigue. The CIS20r focuses on the previous 2 weeks and is considered reliable and valid for measuring fatigue in patients with MS. 20 The CIS20r is widely used in Dutch research studies, and it has been shown to be sensitive to the effects of fatigue interventions in Chronic Fatigue Syndrome, cancer survivors, patient during cancer treatment, patients with neuromuscular disease, and recently also in patients with type 1 diabetes. In order to allow comparisons with other studies, we also included the FSS, the MFIS, and the SF36 vitality scale.
The IPA 15 was used to measure societal participation. This self-report questionnaire measures a person's current perception of the ability of how to live his or her life. The questionnaire includes items such as carrying out domestic activities when one wants, and cooking the way one prefers. 15 The questionnaire consists of 32 questions. Five subscales are distinguished: 1. Autonomy indoors (five items), 2. Family role (seven items), 3. Autonomy outdoors (seven items), 4. Social life and relations (seven items), and 5. Work and education (six items). The score on each IPA domain is the average score on the items of the domain and ranges from 0 to 4, with lower scores indicating better societal participation and autonomy. The IPA is a valid and reliable instrument for assessing autonomy and societal participation in chronic medical disorders. 21 The FSS is a measure of fatigue severity and comprises nine statements that are scored from 1 to 7 (1 = completely disagree; 7 = completely agree). The final score is the mean of the item scores. 16 The MFIS is a 21-item shortened version of the Fatigue Impact Scale; three subscales are distinguished: physical, cognitive, and psychosocial functioning. 17 Higher scores mean a greater impact of fatigue on functioning in the specified domain.
The outcomes of the RAP and the results of the SF36 to describe patients' daily functioning and participation are also reported. The patients' treatment adherence was determined by assessing the number of sessions each participant attended.
Power analysis
The sample size calculation was based on a clinically relevant between-group difference of ⩾8 points on the CIS20r fatigue scale. 22 In total, 90 patients (45 per treatment group) were needed to detect this clinically relevant difference with an standard deviation (SD) of 12.7, 23 a power of 80%, an alpha of 0.05, and a maximum attrition rate of 20%.
Statistical analysis
Statistical analyses were pre-specified and performed with SPSS for Windows statistical software package (Version 22; SPSS, Inc., Chicago, IL). Primary analyses were performed according to the intention-to-treat principle and consisted of all participants (analyzed as randomized).
We used mixed linear models to study the effectiveness of CBT. Mixed-model analysis takes into account the dependency of the repeated observations within the patient. In total, three models were analyzed: (1) a crude model, only adjusted for the baseline value of the particular outcome; (2) a model adjusted for center; scores of patients who belong to the same center are correlated, 23 therefore randomization was stratified per center; (3) a model adjusted for covariates that were likely to have a prognostic influence to improve precision. 24 The covariates were determined a priori: gender, disease severity (EDSS), general self-efficacy (General Self-Efficacy Scale (GSES)), anxiety (HADS, subscale anxiety), and comorbidities (Cumulative Illness Rating Scale (CIRS)) at baseline. For all models, both an overall effect of CBT and the effects of CBT at the different measurement points were estimated. For the latter, time and interaction between group and time were added to the model. Time was thereby treated as a categorical variable represented by dummy variables.
Furthermore, we calculated the absolute risk reduction (ARR), the number needed to treat (NNT), and the 95% confidence interval (CI) for patients who showed an improvement of ⩾8 points on the CIS20r fatigue scale and for patients who scored <35 on the post-treatment measurement (T16). The NNT is the average number of patients who need to be treated for one patient to benefit in comparison to the control group (in this case an improvement of ⩾8 points or a score <35 points). 25 
Results
Participants
The flow chart is displayed in Figure 1 . Between November 2011 and July 2014, 91 patients were randomized, of whom 44 were allocated to CBT and 47 to the MS nurse. Baseline demographic and disease characteristics are displayed in Table 1 .
Three patients (7%) in the CBT study group and eight (17%) in the control study group dropped out during the study. In total, 28 (64%) patients in the CBT study group completed ⩾10 sessions, with a median of 10.5 sessions (interquartile (ICQ 1-3 ): 8.8-11.0). In the control study group, 37 (79%) completed all three MS nurse consultations, with a median 3 of sessions (ICQ 1-3 : 3-3). The demographics of the drop-outs are available in Supplementary Appendix 3.
During the treatment period, one serious adverse event (MS relapse confirmed by a neurologist, followed by inpatient treatment) was reported in the CBT study group, and two (one MS relapse and one gall bladder surgery) were reported in the control study group. During the long-term follow-up period, three serious adverse events (two MS relapses and one surgery) were reported in the CBT study group and one (MS relapse) was reported in the control study group. These events were reported to and judged by the Medical Ethics Committee not to be directly associated with the interventions.
Effect on fatigue and societal participation
The mean scores (SD) of the fatigue and participation outcomes at baseline and follow-up are presented in Table 2 .
The between-group effects of the second model (i.e. adjusted for center) of CBT on fatigue, societal participation, and secondary fatigue outcomes are displayed in Table 3 . The results of the other models are provided in Supplementary Appendix 4.
Post-treatment CIS20r fatigue scores showed a positive treatment effect for CBT compared to the MS nurse intervention (β = −6.7 (95% CI = −10.7; −2.7)) ( Figure 2 ) that gradually wore off during the subsequent 8 months (T52: β = 0.5 (95% CI = −3.5; 4.5)). IPA domain scores did not show between-group differences at any time point, except for a significant between-group effect on the IPA work and education domain at T26 (β = −0.3 (95% CI = −0.7; −0.0)). In addition to the CIS20r fatigue results, the secondary fatigue measures showed comparable scoring patterns during the 1-year study (significant results FSS on T8, T16 and overall; MFIS on T8, SF36 vitality on T8, T16 and overall, see Table 3 ).
The number of participants that showed a clinically relevant change of 8 points or more immediate postintervention (T16) in the CBT-study group was 22 out of 39 patients, and in the control group 9 out of 35. A score below the cut-off of 35 points on the CIS20r fatigue appeared in 21 out of 39 patients in the CBTstudy group, and in 7 out of 35 in the control study group. The ARR of reporting a clinically relevant change of 8 or more points on the CIS20r fatigue scale in the CBT-study group compared to the control study group was 0.31 (95% CI = 0.09; 0.52), with a NNT of 3.3 (95% CI = 1.9; 10.6). The ARR for patients to score below the cut-off of 35 points was 0.34 (95% CI = 0.13; 0.54), with a NNT of 3.0 (95% CI = 1.8; 7.5).
Discussion
This study found a significant beneficial effect of CBT on MS-related fatigue directly following treatment. The significant 6.7 point difference on the CIS20r fatigue found after the 16-week intervention period approached the a priori defined clinically relevant change of 8 points or more. Furthermore, patients scored below the cut-off point of 35 for extreme fatigue, and the secondary fatigue questionnaires show similarly positive and significant results. In addition to these positive effects, the NNT was low at 3.3. The follow-up measurements showed that the positive effects gradually wore off after treatment cessation. Summarizing the results, the study found positive short-term effects of CBT on MS-related fatigue compared to the MS nurse consultations.
The results regarding societal participation were not as positive. Except for one positive and significant result on IPA work and education at T26, we found no significant effect of CBT compared to the MS nurse control condition. The participants did not show substantial limitations on the IPA at baseline, which could be interpreted as a ceiling effect; there was little room for improvement. Furthermore, a note of caution about the interpretation of the IPA is due here; it might not be the most suitable tool to measure societal participation. However, the secondary participation measures, SF36 and RAP, also failed to show significant between-group differences, with the exception of SF36 physical role functioning at T8. This leads us to conclude that CBT for MS-related fatigue did not influence participation in this study.
Some strengths of this study need to be highlighted. First of all, we had a follow-up period of 1 year. Only three studies have provided long-term (8-12 months) follow-up data. 10, 26, 27 A second (methodological) strength of the current study was that we excluded patients with fatigue potentially caused by other factors (e.g. depression, primary sleep disorders). This led to the inclusion of patients with primary MS-related fatigue and the results can therefore be generalized to any ambulant population with primary MS-related fatigue. It should be noted that only 5% of the patient population that was assessed for eligibility was excluded because of high depression scores (see flow chart), which indicates that the vast majority of this source population suffers from pure primary MS-related fatigue. A third strength of the current study was that the therapy was only provided by certified psychologists with CBT training. A fourth strength was that both interventions were delivered by multiple independent therapists, which decreases the risk of contamination between study groups and increases the generalizability of the study results to other clinical settings and therapists. Finally, this is the first study in which CBT was tailored to the patients' needs, that is, only modules were applied that were relevant for the patient as shown by the baseline assessment of perpetuating factors, whereas previous CBT studies used a fixed treatment protocol. 28 Some limitations should be considered when interpreting the results. First, recruitment bias might have occurred toward patients who were highly motivated to start with CBT and who were willing to be treated by a psychologist. 29 The fast drop-out of five persons in the MS nurse study group is likely related to patient preferences and the disappointment about treatment allocation. Furthermore, drop-out and treatment adherence might be caused by attentional problems and impaired working memory. However, the number of drop-outs was still lower than the 20% that we accounted for. Second, in this type of research, it is hard to control for all non-specific treatment effects. However, three MS nurse consultations was the maximum amount of sessions, since providing more sessions would be regarded as an intervention, rather than a control condition. Finally, CBT is an expensive and intensive treatment. However, even more expensive and intensive treatment with unknown effectiveness is provided for MS-related fatigue. Therefore, searching for new methods to provide CBT, with the use of for example e-health methods, might provide a solution.
This study makes several noteworthy contributions to the field of CBT treatment of MS-related fatigue.
The current results seem to be consistent with the Based on the current results, some recommendations can be given. Future research into the factors related to the process of change during CBT may improve CBT for MS-related fatigue. Furthermore, insight into factors related to the diminishing post-treatment effects might aid the improvement of the current CBT program or the development of interventions that are able to sustain a positive short-term effect over the long term (e.g. CBT booster sessions). The evidence provided by this randomized clinical trial supports a clinical practice recommendation to start CBT in patients with severe MS-related fatigue.
Conclusion
The TREFAMS-CBT trial showed a significant and beneficial short-term effect of individually tailored CBT provided by certified psychologists compared to the control intervention on MS-related fatigue. Future research should focus on identifying the mechanisms of change to provide a basis for maintaining positive effects over the long term.
